Zytrav Eye Drop contains Travoprost 0.004% w/v, a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost acts by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby effectively lowering IOP and reducing the risk of optic nerve damage and visual field loss. Zytrav Eye Drop is administered topically, typically as one drop in the affected eye(s) once daily in the evening. The medication is well-tolerated, although some patients may experience mild ocular side effects such as eye redness, irritation, or increased pigmentation of the iris and eyelid. Systemic adverse effects are rare due to minimal systemic absorption. Caution is advised in patients with a history of ocular inflammation or herpes simplex virus keratitis. Zytrav Eye Drop should not be used during pregnancy or lactation unless clearly necessary, and patients should inform their healthcare provider of any concurrent medications or ocular conditions. Regular monitoring of intraocular pressure and ocular health is recommended during treatment to assess efficacy and detect potential adverse effects. Zytrav Eye Drop offers a safe and effective option for managing elevated IOP in glaucoma and ocular hypertension patients.